Clinical Impact of Hypercalcemia in Kidney Transplant
Hypercalcemia (HC) has been variably reported in kidney transplanted (KTx) recipients (5–15%). Calcium levels peak around the 3rd month after KTx and thereafter slightly reduce and stabilize. Though many factors have been claimed to induce HC after KTx, the persistence of posttransplant hyperparathy...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.4061/2011/906832 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850220667734065152 |
|---|---|
| author | Piergiorgio Messa Cosimo Cafforio Carlo Alfieri |
| author_facet | Piergiorgio Messa Cosimo Cafforio Carlo Alfieri |
| author_sort | Piergiorgio Messa |
| collection | DOAJ |
| description | Hypercalcemia (HC) has been variably reported in kidney transplanted (KTx) recipients (5–15%). Calcium levels peak around the 3rd month after KTx and thereafter slightly reduce and stabilize. Though many factors have been claimed to induce HC after KTx, the persistence of posttransplant hyperparathyroidism (PT-HPT) of moderate-severe degree is universally considered the first causal factor. Though not proven, there are experimental and clinical suggestions that HC can adversely affect either the graft (nephrocalcinosis) and other organs or systems (vascular calcifications, erythrocytosis, pancreatitis, etc.). However, there is no conclusive evidence that correction of serum calcium levels might avoid the occurrence of these claimed clinical effects of HC. The best way to reduce the occurrence of HC after KTx is to treat as best we can the secondary hyperparathyroidism (SHP) during the uraemic stages. The indication to Parathyroidectomy (PTX), either before or after KTx, in order to prevent or to treat, respectively, HC after KTx, is still a matter of debate which has been revived by the availability of the calcimimetic cinacalcet for the treatment of PT-HPT. However, we still need to better clarify many points as regards the potential adverse effects related to either PTX or cinacalcet use in this clinical set, and we are waiting for the results of future randomized controlled trials to achieve some more definite conclusions on this topic. |
| format | Article |
| id | doaj-art-75b664c557ad4dbd899575d5100e4e65 |
| institution | OA Journals |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-75b664c557ad4dbd899575d5100e4e652025-08-20T02:06:58ZengWileyInternational Journal of Nephrology2090-214X2090-21582011-01-01201110.4061/2011/906832906832Clinical Impact of Hypercalcemia in Kidney TransplantPiergiorgio Messa0Cosimo Cafforio1Carlo Alfieri2Nefrologia, Dialisi e Trapianto Renale, Ospedale Maggiore-Policlinico-Mangiagalli-Regina Elena, IRCCS, 20122 Milano, ItalyNefrologia, Dialisi e Trapianto Renale, Ospedale Maggiore-Policlinico-Mangiagalli-Regina Elena, IRCCS, 20122 Milano, ItalyNefrologia, Dialisi e Trapianto Renale, Ospedale Maggiore-Policlinico-Mangiagalli-Regina Elena, IRCCS, 20122 Milano, ItalyHypercalcemia (HC) has been variably reported in kidney transplanted (KTx) recipients (5–15%). Calcium levels peak around the 3rd month after KTx and thereafter slightly reduce and stabilize. Though many factors have been claimed to induce HC after KTx, the persistence of posttransplant hyperparathyroidism (PT-HPT) of moderate-severe degree is universally considered the first causal factor. Though not proven, there are experimental and clinical suggestions that HC can adversely affect either the graft (nephrocalcinosis) and other organs or systems (vascular calcifications, erythrocytosis, pancreatitis, etc.). However, there is no conclusive evidence that correction of serum calcium levels might avoid the occurrence of these claimed clinical effects of HC. The best way to reduce the occurrence of HC after KTx is to treat as best we can the secondary hyperparathyroidism (SHP) during the uraemic stages. The indication to Parathyroidectomy (PTX), either before or after KTx, in order to prevent or to treat, respectively, HC after KTx, is still a matter of debate which has been revived by the availability of the calcimimetic cinacalcet for the treatment of PT-HPT. However, we still need to better clarify many points as regards the potential adverse effects related to either PTX or cinacalcet use in this clinical set, and we are waiting for the results of future randomized controlled trials to achieve some more definite conclusions on this topic.http://dx.doi.org/10.4061/2011/906832 |
| spellingShingle | Piergiorgio Messa Cosimo Cafforio Carlo Alfieri Clinical Impact of Hypercalcemia in Kidney Transplant International Journal of Nephrology |
| title | Clinical Impact of Hypercalcemia in Kidney Transplant |
| title_full | Clinical Impact of Hypercalcemia in Kidney Transplant |
| title_fullStr | Clinical Impact of Hypercalcemia in Kidney Transplant |
| title_full_unstemmed | Clinical Impact of Hypercalcemia in Kidney Transplant |
| title_short | Clinical Impact of Hypercalcemia in Kidney Transplant |
| title_sort | clinical impact of hypercalcemia in kidney transplant |
| url | http://dx.doi.org/10.4061/2011/906832 |
| work_keys_str_mv | AT piergiorgiomessa clinicalimpactofhypercalcemiainkidneytransplant AT cosimocafforio clinicalimpactofhypercalcemiainkidneytransplant AT carloalfieri clinicalimpactofhypercalcemiainkidneytransplant |